Mrna-4203
Synovial Sarcoma
Immatics US, Inc.Phase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 89/ 100
Competitive context
22 Active assets in the Synovial Sarcoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Tazemetostat Epizyme, Inc. | Phase 2 | BB |
Cyclophosphamide Zelluna Immunotherapy AS | Phase 2 | BB |
Pembrolizumab Valo Therapeutics Oy | Phase 2 | B |
Cixutumumab National Cancer Institute (NCI) | Phase 2 | B |
Sorafenib National Cancer Institute (NCI) | Phase 2 | B |
View all 36 →
Same molecule, other indications
Mrna-4203 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →